Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Caliper Life Sciences Awarded EPA Contract

Published: Tuesday, April 10, 2007
Last Updated: Tuesday, April 10, 2007
Bookmark and Share
Caliper Discovery Alliances and Services unit will test environmental chemicals under EPA’s ToxCast research program.

Caliper Life Sciences, Inc. has announced that the United States Environmental Protection Agency (EPA) has awarded a contract to NovaScreen Biosciences, the in vitro discovery services arm of Caliper Discovery Alliances and Services (CDAS), to assist the agency in developing new approaches to identify toxic environmental chemicals.

The contract award, which was anticipated by Caliper, will range from $1.4 to $69 million over the course of two to five years. The specific dollar value within this range will be based primarily upon the volume of testing requested by the EPA and the availability of funds for future years.

As part of the EPA’s ToxCast research program, CDAS will utilize biochemical and cellular assays, validated in the pharmaceutical drug discovery industry, to help predict how chemicals such as pesticides will interact with the environment, humans and animals.

CDAS will leverage its screening tools and its proprietary Side-Effect Database (SED), representing screening results from 2,300 compounds tested against more than 70 biological targets, to provide comprehensive laboratory testing and analysis services across a broad range of specific protein targets of interest to the EPA.

“A contract of this magnitude validates industry demand for CDAS; organizations require a reliable service-oriented provider of leading-edge technologies that delivers timely, high quality results,” said Kevin Hrusovsky, CEO of Caliper Life Sciences.

“Our work with the EPA is an extension of the services we successfully provide for our pharma and biotech customers,” Hrusovsky continued.

“The EPA needed a partner to perform fast, accurate screening of a high volume of compounds and the technical expertise to help build relevant predictive datasets,” said David Manyak, Ph.D., executive vice president of discovery services of Caliper Life Sciences.

“CDAS was selected by the EPA, in a highly competitive award process, based on our superior technical proposal, data quality plan and value offering. We are gratified by this validation of our capabilities and excited to work with the EPA on this important program that will result in a healthier, safer environment,” Manyak added.

Caliper Discovery Alliances & Services (CDAS) is the newly-formed services organization created from the integration of NovaScreen Biosciences, a provider of in vitro discovery services, and Xenogen Biosciences, a provider of in vivo discovery services.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Caliper LS Receives $1.1 Million Task Order from the EPA's ToxCast™ Screening Program
This task order was issued pursuant to a contract that Caliper was awarded by the EPA in April 2007 under the ToxCast program.
Wednesday, August 20, 2008
Caliper Life Sciences Forms Alliance with Horizon Discovery
CDAS expands offering to include screening for targeted cancer drugs using genetically-defined in-vitro human disease models.
Thursday, April 10, 2008
Caliper Life Sciences Launches Drug Discovery and Development Services Business
Caliper combines in vitro and in vivo services of Novascreen Biosciences and Xenogen Biosciences to form Discovery Alliances & Services.
Tuesday, January 09, 2007
Caliper Strengthens Distribution Channels in China, Hong Kong and India
Leading international distributors expand customer access to Caliper microfluidics and drug discovery technologies.
Monday, February 13, 2006
Caliper Completes Acquisition of NovaScreen
The acquisition combines NovaScreen's screening, profiling and assay development services with Caliper's LabChip® and liquid handling products.
Thursday, October 06, 2005
Caliper Technologies expands Caliper 250 system

Monday, March 10, 2003
Caliper cut's Amphora Discovery's purchase obligations

Tuesday, December 17, 2002
Zymark Supplies HTS Systems to Vertex Pharmaceuticals

Tuesday, October 15, 2002
Scientific News
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos